Stock analysts at StockNews.com began coverage on shares of Culp (NYSE:CULP – Get Free Report) in a note issued to investors on Thursday. The brokerage set a “hold” rating on the textile maker’s stock.
Culp Stock Up 2.0 %
Shares of CULP opened at $5.13 on Thursday. The stock has a market cap of $64.07 million, a P/E ratio of -3.46 and a beta of 1.22. The business’s 50 day moving average price is $5.73 and its 200-day moving average price is $5.05. Culp has a 52 week low of $4.25 and a 52 week high of $6.85.
Culp (NYSE:CULP – Get Free Report) last released its earnings results on Wednesday, September 4th. The textile maker reported ($0.37) EPS for the quarter. The company had revenue of $56.54 million during the quarter. Culp had a negative return on equity of 19.51% and a negative net margin of 7.88%.
Insider Buying and Selling
Hedge Funds Weigh In On Culp
A hedge fund recently raised its stake in Culp stock. Vanguard Group Inc. raised its position in Culp, Inc. (NYSE:CULP – Free Report) by 4.2% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 485,420 shares of the textile maker’s stock after acquiring an additional 19,640 shares during the quarter. Vanguard Group Inc. owned approximately 3.89% of Culp worth $2,330,000 at the end of the most recent quarter. Institutional investors and hedge funds own 75.05% of the company’s stock.
Culp Company Profile
Culp, Inc manufactures, sources, markets, and sells mattress fabrics, sewn covers, and cut and sewn kits for use in mattresses, foundations, and other bedding products in the United States, North America, the Far East, Asia, and internationally. It operates in two segments, Mattress Fabrics and Upholstery Fabrics.
Featured Stories
- Five stocks we like better than Culp
- The Role Economic Reports Play in a Successful Investment Strategy
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
- How to Invest in Insurance Companies: A Guide
- Top-Performing Non-Leveraged ETFs This Year
- How to Invest in Biotech Stocks
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Receive News & Ratings for Culp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Culp and related companies with MarketBeat.com's FREE daily email newsletter.